Cell study · human and murine macrophages

LL-37 drove IL-1β and IL-18 release from human and murine macrophages

Checked against the paper Cell studyPublished by PepVault

The takeaway

In lab cells, LL-37 acted as a trigger for inflammatory signals, and more strongly in lupus patients' macrophages; it was not tested as a treatment.

Kind
Cell study
Studied in
Human and murine macrophages
Published
2013
Journal
J Immunol

What they tested

The team tested whether neutrophil extracellular traps (NETs), and LL-37, a germ-fighting protein carried on them, switch on the inflammasome in macrophages, and whether that response is different in lupus.

How the study was done

A lab study in cells: human and murine macrophages were exposed to NETs or to LL-37, and macrophages from people with systemic lupus erythematosus were compared with others. The team also treated human neutrophils with IL-18.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking LL-37? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In human and murine macrophages, both NETs and LL-37 turned on caspase-1, the core enzyme of the inflammasome, and the cells released active IL-1β and IL-18, two inflammatory signals. LL-37 switched on the NLRP3 inflammasome through potassium leaving the cell via the P2X7 receptor. This response to NETs and LL-37 was stronger in macrophages taken from lupus patients. In human neutrophils, IL-18 in turn triggered NETosis, the process of forming NETs.

What it doesn’t show

This was cell work, so it is not a result in people, and it did not track lupus flares or organ damage. The self-feeding inflammation loop the authors describe is their reading of the cell results, not something measured in patients.

The paper

Kahlenberg et al. Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J Immunol. 2013.

The compound

More studies on LL-37

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking LL-37? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo